newsfilter
← Latest News
GlobeNewswire·

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), a Canadian clinical stage pharmaceutical